|
|
Monoclonal body against amyloid beta Options of immune body or its epitope-linking fragment, that are specific in terms of beta amyloid peptide 1-40 are suggested. Each option is characterized in that contains areas VH and VL, or 6 CDR out of light and heavy chains. Described: coding nucleic acid; options of repository lines of cells (hybrid) with collection numbers DSM ACC2844, DSM ACC2845, DSM ACC2846, and line of cells including said polynucleotide, to receive immune bodies. Suggested: therapeutic composition to treat diseases or distresses due to or linked with amyloid or amyloid-like proteins, and set to determine amyloid protein in the biologic sample, - using immune body. Options of method of immune body production are described: with use of hybrid and coding nucleic acid. Described: method of diagnostic of aptitude for disease or state linked with amyloidosis; method of determination of degree of content of amyloidogenic plaque in the tissue; method of monitoring of minimum residual disease linked with amyloid; method of forecast of individual sensibility; method of treatment or alleviation of the diseases linked with amyloidosis; method of decreasing of number of plaque and their load in brain; mewthod of decreasing of total number of soluble protein of amyloid, and method of keeping or increasing of cognitive memory volume of the individual - using immune body or its epitope-linking fragment. Options of use of immune body or its epitope-linking fragment for medicament production are described. |
|
|
Enterococcus faecium Ef79OSAU strain having antagonist activity in relation to the bacteria of Listeria genus and Enterococcus faecalis species is deposited in State collection of microorganism and normal flora of FBIS MNIIEM named after G.N. Gabrichevsky of Rospotrebnadzor under registration No. 1251, and can be used to prepare the probiotic specimen. |
|
|
Method of treating bone tumours and tumour-like bone disorders Invention refers to medicine, namely bone oncology, and can be used for treating bone tumours and tumour-like bone disorders. That is ensured by separating a pathological focus, excising the tumour or tumour-like disorder, performing a cryoexposure on the post-excision bone defect three times and closing the wound. The cryoexposure is ensured by 'Medical Cryoapplicator' by placing its balls on a surgical suture into the post-excision bone defect and cooling with liquid nitrogen for 10-60 s. That is followed by thawing in normal saline heated to plus 38°C. After the three cryoexposures, 'Medical Cryoapplicator' is removed. A post-excision defect is repaired if indicated. |
|
|
Group of inventions deals with BCG-based immunobiological medication of treating urinary bladder cancer, which additionally contains enzyme or enzymes with provision of cleavage of secretion of urinary bladder mucosa membrane and buffer, taken in therapeutically effective ratio. Group of inventions also deals with method for application of immunobiological medication for treating urinary bladder cancer, consisting in introduction of said immunobiological medication into urinary bladder. |
|
|
Immunometabolic formulation with antimicrobial activity Invention refers to veterinary science and is applicable for a preventive and intensive therapy of purulent septic and gastrointestinal focal diseases, stimulation of immunity system and metabolic processes in animals. Object of the invention is a method for producing a new formulation based on iodine, succinic acid and ASD second fraction, possessing immunometabolic and antimicrobial activity. |
|
|
Invention relates to the pharmaceutical industry, in particular to the application of a coniferous provitamin concentrate, to a medication based on the coniferous provitamin concentrate, a pharmaceutical composition, containing the coniferous provitamin concentrate, and to a method of the prophylaxis and treatment of benign prostate hyperplasia. |
|
|
Using ep4 receptor antagonists in treating il-23-mediated diseases Invention refers to a compound with EP4 receptor antagonist activity or its pharmaceutically acceptable salt, which is effective in treating an immune disease or allergy. This invention also refers to a compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt with EP4 receptor antagonist activity, which is effective in treating an immune disease or allergy. This invention also refers to a pharmaceutical composition for treating an immune disease or allergy, which contains a therapeutically effective amount of the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt. |
|
|
Therapeutic nutrient composition Therapeutic nutrient composition containing a mix of dihydroquercetin, sodium alginate and ascorbic acid taken in certain mixture ratio. |
|
|
Kinetotherapy device comprising a ceiling structure, drive pipes of which bear support beams, pelvis, legs and head supports; tension sensors connected to ropes are rigidly integrated into the support beams; outputs of the tension sensors are connected to a converter by means of a pivot attached to the support beam. The effect is ensured by the user-friendly objectification of the therapeutic process and the converter prompts. |
|
|
Absorbent product containing temperature sensor Invention refers to an absorbent product (1) containing: a temperature sensor (5) and at least one temperature changing material (6) arranged so that the given material is capable of adjusting a temperature change caused by excrement inflow, and so that the above temperature sensor (5) is capable of sensing the above adjusted temperature change. The invention also refers to a system for detection of the excrement inflow into the absorbent product (1); the above system comprises the absorbent product (1) according to the invention, configured to form an output temperature signal, and a processor unit (8) configured to generated the signal produced by the temperature sensor (5). The processor unit (8) is configured to detect the temperature changes, which are adjusted by the temperature changing material (6), and detect the excrement inflow into the absorbent product (1) on the basis of the above temperature change if the excrement inflow is accompanied by the temperature change. |
|
|
Wireless identificaton system for absorbing product Alarm system is described, which indicates the change in the absorbing product, such as presence of liquid emanations of human body. The described alarm system does not contain any conducting elements inside the product as it has been required in the past. Instead, the changes are traced from the external coating of the product. The alarm device is provided for identification and indication of presence of emanations of human body in the absorbing product. The device comprises the housing and the capacitor sensor adapted to sense the changes in capacity caused by emanations in the absorbing product. The alarm device can comprise the attachment mechanism for demountable attachment of the housing to the absorbing product. |
|
|
Respective components of absorbent article for uniform appearance Method of production of a disposable absorbent article is provided, having a plurality of components, comprising selection of a first material suitable for use as an outer cover; production of a basic element comprising the outer cover. The outer cover comprises a central area of the outer cover, having a central area texture of the outer cover; and selection of a second material suitable for use as an elastic panel. The second material is different from the first material. The method also provides the production of the first elastic panel having a central area of the first elastic panel; and attachment of the first elastic panel to the basic element. Selection is carried out so that the central area of the first elastic panel provides the appearance identical in the texture to the central area of the outer cover. |
|
|
Bearing construction for positioning of patient with translator of patient's body movement Invention relates to constructions, used as the bearing and support of a patient in a desirable position during medical examination and treatment. The bearing construction for the patient includes a pair of supports with independent height regulation, each of which is connected to a support for the patient. The supports can be independently on each other lifted, lowered, rolled or turned around the longitudinal axis, moved in the transverse direction and installed at an angle, directed upwards or downwards. Sensors for the measurement of all the said movements are provided. The said sensors transmit data for the coordinated regulation and support of internal ends of the supports for the patient in an appropriate position during all such movements into the computer. A longitudinal translator of movements provides compensation in the construction length when the supports are installed at an angle, directed upwards or downwards. The translator of the patient's body movements provides the coordinated translational movement of an upper part of the patient's body along a respective support for the patient in the patient's feet direction or in the head direction, when the supports for the patient are installed at an angle to each other, directed upwards or downwards, to support appropriate spine biomechanics and prevent excessive stretching or compression of the spine. |
|
|
Set for preparation of cervical-uterine slime of sows Set for preparation of cervical-uterine slime of sows contains the cylindrical foamed rubber tampon stitched with mylar thread with formation of loop in the form of triangle the base of which passes along the diameter of one of tampon end faces, and the top coincides with the centre of the second end face of the tampon from which both ends of thread emerge to the length, minimum ten times exceeding the tampon length, and the device for placement of tampon in uterus neck. The device for placement of tampon in uterus neck is implemented in the form of two metal parts, each of which consists of a bed fitted with a handle for tampon which is a chamfer narrowed towards top and rounded off on the ends, the length and width which are sufficient for tampon placement. The bed for tampon of one of parts is a specular reflection of the tampon bed of another part, and each handle is implemented in the form of chamfer for the purpose of placement one in another for fixing of both parts with reference to each other. |
|
|
Silicone hydrogel lenses with water-enriched surfaces Invention relates to silicone hydrogel contact lens. Contact lens possesses layered structural configuration and gradient of water content from internal to external part of silicone hydrogel contact lens. Lens includes silicone hydrogel core or volumetric material, fully covered with external hydrogel layer, possessing thickness, equal not less than 0.1 mcm, measured by means of atomic power microscopy on section from posterior surface to anterior surface of silicone hydrogel contact lens in completely hydrated condition. External hydrogel layer mainly does not contain silicon. Content of water in external hydrogel layer is not less than 1.2 times larger than content of water in silicone hydrogel volumetric material in completely hydrated condition. |
|
|
Method involves analysing risk factors and calculating a probable poor prognosis. A comprehensive medication adherence following a coronary bypass surgery (PR) is first determined by formula. A probability of the poor prognosis (Y) is calculated by formula. The risk of the poor prognosis is considered to be very low if Y varies from 0 to 0.28; Y from 0.29 to 0.4 shows the low risk; the moderate risk is stated if Y is 0.41-0.55; the risk of the poor prognosis is high provided Y is 0.56-0.7, whereas the very high risk is stated if Y ranges from 0.71 to 1. |
|
|
Method for choosing orthokeratology contact lenses in children and adolescents with myopia Prior to and after choosing an orthokeratology contact lens, a conventional diagnostic examination is performed. An adaptation behaviour is assessed at every stage of the examination by performing a confocal corneal microscopy in addition to the conventional diagnostic examination. The chosen orthokeratology contact lenses are placed on the surface of the patient's cornea, kept thereon with following up the next morning, 7 days later, one month later and every 3 months for a year. Active keratocytes are detected and quantified in an anterior corneal stroma according to the confocal corneal microscopy findings. If their rate is more than 10, the cytomorphological changes of the cornea are considered to go beyond the norm that requires a keratoprotective therapy to be included, which is supposed to be followed by replacing or cancelling the orthokeratology contact lens if the adaptation behaviour while wearing this contact lens appeared to be unachieved. |
|
|
Method of diagnosing latent tuberculosis of extrapulmonary localisation Provocative subcutaneous tuberculin test is performed. Stress level is additionally diagnosed by Angioscan device. If stress level increases by 90% and more, latent tuberculosis of extrapulmonary localisation is diagnosed. |
|
|
Method for preparing mastoidal cavity for mastoid repair Cotton swab wetted in 4% indigo carmine is immersed into a formed mastoidal cavity. The swab is supposed to fill the entire cavity. After the 10-minute exposure, the swab is removed. The remained mucous membrane coloured in blue is removed completely under control of a surgical microscope. A mastoid repair is performed. |
|
|
Method for surgical management of pancreatic head cysts Surgical management of a pancreatic head cyst involves dissecting a pyloric part away from a stomach. A posterior wall of the pyloric part is incised. An anterior wall of the pancreatic head cyst is incised. An anastomosis is formed between the pyloric part and the cyst cavity. The pyloric part is closed tightly with a one-row suture. The discontinuity of the gastrointestinal tract is repaired by applying the anastomosis between the stomach and jejuneum. |
|
|
Method of treating patients with incipient signs of epiretinal membrane Invention aims at treating the patients with incipient signs of epiretinal membrane (ERM). A laser device is used to coagulate an epiretinal membrane area at contact thereof with a retina. A laser light wavelength is 577 nm; a power is 100-200 W; an exposure length is 20-25 ns; a pulse rate is 10-15%; a spot diameter is 100 mcm; the coagulate number is 50-150. |
|
|
Method for selecting approximated lead points ECG electrodes are placed on the skin of a patient's left pectoral area in certain points. Point 1 - a standard ECG electrode attached to a right arm is placed in the 2nd intercostals space along a left parasternal line. Point 2 - a standard ECG electrode attached to a left arm is placed in the middle of a left deltoid pectoral sulcus. Point 3 is localised by means of an original formula taking into account the anatomical parameters of the patient's chest. A standard ECG electrode attached to a left leg is placed into point 3. Herewith, 6 approximated ECG leads are recorded: Ia is a bipolar record from point 1 to point 2, IIa is a bipolar record from point 2 to point 3, IIIa is a bipolar record from point 3 to point 1, aVRa is a unipolar augmented record from point 1, aVLa is a unipolar augmented record from point 2, aVFa is a unipolar augmented record from point 3. |
|
|
Diagnostic technique for prostate cancer Technique involves prostate tomography followed by intravenous administration of a water-soluble contrast agent, which is presented by 50 ml of an iodine-containing non-ionic substance at a rate of administration of 5-7 ml/s. The tomography is performed in the dynamic mode by multispiral X-ray computed tomography in the three-dimensional mode 15, 18, 21, 24, 27, 30, 40, 45, 60, 70, 80 seconds from the moment of the administration of the contrast agent, at a slice thickness of 0.5mm. The formed images are analysed by constructing time variation curves of densitometric density of each volume picture element of the prostate and external iliac artery (EIA). A maximum average densitometric density of the EIA is calculated. Further, by each curve for each moment of time, a difference of the densitometric density of the volume picture element at this and following moment of time is determined by each curve; a segment with the maximum difference of the densitometric density is detected, and its maximum difference is related to the length of this segment. The derived value is further related to the maximum average density of the EIA. The calculated values reflex a specific volumetric blood flow in the volume picture element. The volumetric blood flow values for all the volume picture elements are used to plot a prostate perfusion chart, wherein the segments of the high volumetric blood flow corresponds to the tumour. |
|
|
LDF and capillaroscopy initial parameters are determined. Recommended antianginal preparations are administered one by one for 3 days. Each following preparations is administered 5 excretion half-lives after the previous one, and each course is followed by determining the LDF parameters. That involves assessing: vascular reaction of skin microcirculation, functional health of tonus-forming mechanisms of blood flow modulation: endothelial - Ae, neurogenic - An and myogenic - Am, respiratory blood flow variations - Av, pulse blood flow variations - As, as well as the capillaroscopy parameters that is a pericapillary area - PA. The LDF and capillaroscopy (PA) initial parameters are compared to those obtained after the preparations tested are administered, and the most optimum preparation which makes the parameters Ae, An, Am and As normalise with Av≤0.08, PA = 105±15 is selected for a continuous therapy. |
|
|
Water vapour-impermeable flexible tube for packing purposes Described is flexible tubular package, intended for catheter for intermittent catheterisation. Catheter for intermittent catheterisation is covered with hydrophilic coating, which becomes slick in contact with swelling-causing medium. Also described is packing set, which contains tubular package, catheter of intermittent catheterisation and swelling-causing medium. |
|
|
Method of treatment of cellulite Invention is a cosmetic method of treatment of cellulite, comprising application to skin in need of treatment of cellulite, of a composition comprising pavlovnine or a polar extract of Paulownia tomentosa timber. |
|
|
Compositions containing paulownin and/or paulownia extracts and using same Invention refers to cosmetology, and represents a method for reducing signs of skin ageing involving applying an effective amount of an extract on skin for reducing signs of ageing; the extract is specified in a group consisting of polar extract from Paulownia tomentosa wood, polar extract from Paulownia fortune wood, polar extract from Paulownia elongate wood, polar extract from Paulownia kawakamii wood and a combination of the two or more of them, wherein the above extracts contain paulownin. |
|
|
Method of prevention and treatment of infectious diseases of birds Method comprises spraying of 1.3% antiseptic solution of the preparation "Iodprotectine" in the form of mist at the rate of 3.0 ml/m3 with 10-, 15-, 30-minute exposure and antiseptic treatment of hatching eggs before laying to the incubator with the method of irrigation of the shell surface at the rate of 10 l per 7000 eggs. Also, the internal surfaces of hatchers are treated with spray at a rate of 1.5 l per 30 m2 with exposure of 15 minutes. |
|
|
Individual is examined to measure serum albumin, total cholesterol and high-density lipoprotein (HDL). The serum albumin level making at least 1.5 g/dl, and the total cholesterol level making at least 40 mg/dl, and/or the high-density lipoprotein level making at least 20 mg/dl require administering an emulsion. The emulsion contains (i) a phospholipid, (ii) a neutral lipid and (iii) a cholate salt. |
|
|
Present invention refers to a kit applicable in a prognostic method in vitro for detecting or predicting in vivo therapeutic response in involved cells or tissues to treating a disease having an aetiology related to cell overproliferation, with the use of a cardiac glycoside. The described kit is used to detect a ratio of isoforms of Na,K-adenosine triphosphatase α-subunits in the involved cells or tissues. The above kit may be used to predict individual's cancer or tumour sensibility to the therapeutic treatment with a cardiac glycoside. |
|
|
Method for facial rejuvenation consists in subdermal and intramuscular injections of botulinum toxin type A containing 500 units and diluted in normal saline in the pre-determined points of problem areas. |
|
|
Invention relates to field of medicine and represents stent for implantation into vessel, which has at least one surface from metal, which in expanded state in vessel adjoins inside to its wall, stent is provided with applied on its surface mixture of bioresorbable binding substance, which represents oligomer, based on lactic and glycolic acids, length of chains in which is sufficiently short for biological decomposition of oligomer in implanted state to take place within approximately 6 weeks, and active substance. |
|
|
Antiretroviral compounds and use thereof Invention refers to new compounds of formula (I) and their pharmaceutically acceptable salts, which inter alia inhibit hepatotropic hepatitis C virus and are applicable in treating hepatitis C virus. In formula (I) R1 is specified in a group consisting of |
|
|
Novel compounds and compositions for targeting at malignant stem cells Invention relates to polymorphs, namely to polymorph 2-acetyl-4H,9H-naphto [2,3-b]furane-4,9-dione, characterised by X-ray diffraction pattern, in fact similar to the one on fig.2, and polymorph of 2-acetyl-4H,9H-naphto [2,3-b]furane-4,9-dione, characterised by X-ray diffraction pattern, in fact similar to the one, given on fig. 3, naphthofurane compounds in form of particles, pharmaceutical compositions for treating cancer, containing one or several naphthofurane compounds, purified compositions for treating cancer, containing one or several said naphthofurane polymorphs in form of particles, methods for obtaining said naphthofurane polymorphs, method for treating cancer in subjects requiring it and method for prolongation of progression-free survival (PFS) in patient with cancer with application of said naphthofurane compounds. |
|
|
Modifiers of glycoprotein vi representing nucleic acid Ligand of glycoprotein VI (GPVI) is suggested, it represents nucleic acid interacting with glycoprotein of thrombocytes GPVI, and modulates its activity with regulation of thrombocytes function. The ligand has secondary structure containing in direction from 5' to 3' a first stalk, a first loop, a second stalk, a second loop, a third loop, a third stalk and a forth loop. The forth loop contains UAA. The ligand sequence is modified to increase resistance to nucleases. The ligand can be used for inhibition of the thrombocyte aggregation. Besides the modulators inhibiting the ligand activity with restoration of GPVI function are suggested. As well the invention relates to the compositions containing ligand or modulator intended for medical treatment of the thrombocytes-mediated disorders. |
|
|
Recognising user's physiological reaction by means of breast pump Group of inventions refers to medicine. A breast pump comprises a funnel and a drive. A sensory unit comprises a user's physiological reaction recognition sensor connected to a control unit. The control unit is configured to compare the recognised physiological reaction to those stored in a memory unit and specifying a milk supply reflex, and set a signal to the drive to initiate the change of breast pump operation with regard to the milk supply reflex recognised. The sensory unit is mounted over a distance from a milk expression region and the breast pump funnel. What is disclosed is a method for controlling the breast pump operation. |
|
|
Method of prediction of stability limit of animals to severe hypoxia after hypoxic preconditioning Intact animals are tested in the behavioural model test of pre-stimulation inhibition of acoustic startle response, determining the relative value of reducing the amplitude of the individual response to intense sound signal (ISS). Then they are subjected to moderate hypoxic preconditioning. After that according to ISS value the amount of ISS the stability limit of the body to severe hypoxia (Tsec) is determined, using the previously revealed reference correlation dependence using the Pearson correlation analysis Tsec = f (ISS). For obtaining the least, ISS is determined in a similar manner preliminary in other intact animals of the same species. They are then subjected to a similar moderate hypoxic preconditioning. After that, the animals are placed in conditions of severe hypoxia, and the value of the stability limit to it is determined by the time of the onset of signs of the animal agony. |
|
|
Control elements for pivoted surgical device Invention refers to medicine. An electrosurgical device comprises a body, end effector, cutting element and rod. The end effector comprises a pair of branches and at least one electrode. The electrode provides RF energy output into the tissues clamped by the branches. The cutting element is designed for cutting the tissue clamped by the branches. The rod comprises a pivot portion, which allows turning the end effector selectively in relation to the rod. The body comprises a control mechanism. The control mechanism may comprise a release trigger. The trigger actuates the cutting element. |
|
|
Group of inventions refers to pharmaceutics. What is described is an aqueous pharmaceutical solution containing 2-(hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one or its pharmaceutically acceptable salt and pH-controlling agent. The above agent is specified in pharmaceutically acceptable organic or inorganic acids, pharmaceutically acceptable acid buffers or any mixture thereof. What is also described is using the above aqueous pharmaceutical solution for producing a drug for treating a disease specified in hyperproliferative diseases, autoimmune diseases and cardiac diseases. |
|
|
Novel application of il-1β compounds Group of inventions relates to the field of medicine. In particular the group of inventions relates to the application of an antibody to IL-1β for the treatment and prevention of Familial Mediterranean fever, for the creation of a medication for the treatment of Familial Mediterranean fever, as well as to the pharmaceutical composition. |
|
|
Method for making endosseous carbon-coated dental implant Method for making an endosseous carbon-nanocoated dental implant involves processing an implant surface with argon ions accelerated to 1 keV at a pressure of (2-6)·10-2 Pa with supplying a negative offset voltage onto a carrier to be increased from 800 to 1,500 V for at least 1 hour; multilayer coating of two alternating layers in the total number of 20-30 is sprayed onto the implant base; a thickness of each layer is 50-100 nm; a carbon nanocoating of a thickness up to 1 mcm is sprayed onto the above coating. The first layer of the multilayer coating consisting of compounds of titanium and carbon is sprayed together with arc spraying of a titanium cathode and pulse-arc spraying of a graphite cathode with increasing carbon concentration in each following layer to the overall increase in the concentration in these layers from 14 to 75 wt %; the second layer consisting of solid amorphous diamond-like carbon having a hardness of 70-100 GPa is applied by pulse-arc spraying of the graphite cathode in the environment of diamond-like film condensation at a temperature of no more than 150°C and a carbon ion power of no more than 100 eV. |
|
|
Method of increasing levomycetinum (chloramphenicol) efficiency 5 g of levomycetinum are dissolved in 100 ml of distilled water, activated with silver ions in concentration 1.0 mg in 100 ml, first polymerisation of levomycetin solution with glutaraldehyde is carried out at 40°C for 2-3 days, after which second polymerisation of levomycetin solution is carried out with 0.2-0.3% of etonium at 40°C for 2-3 days, with content of glutaraldehyde and etonium in 100 ml of solution constituting 0.1% and 0.2-0.3% respectively. |
|
|
Method of treatment diarrhoea in new-born calves Against the background of provision of conventional known feeding conditions and management of calves aged 1-5 days at a dose of 2 cm3 once a day intramuscularly 2 times at intervals of 72 hours the drug imaktin is administered. |
|
|
Antithrombotic agent of siberian fir cellulose Antithrombotic agent of sulphated cellulose material represents cellulose sulphate produced of partially hydrolysed wood substance of Siberian fir by sulphating by means of a complex of pyridine and chlorosulphonic acid. |
|
|
Specific combined therapy of malignant tumours with cytostatic agent and its modifying agent One or more cytostatic agents are administered in an amount of 1/4 to Ѕ of a standard therapeutic dose, which is followed by a subcutaneous administration of N-acetyl-D-glucoaminyl-β-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) in an effective amount once a day for 4-20 days. |
|
|
Veterinary implantable retard drug (versions) Veterinary implantable retard drug, comprising melatonin and biodegradable polymeric base. The polymeric base is used as biological adhesive "Sulphacrylate" with the following ratio of components, wt %: melatonin - 5-50, adhesive "Sulphacrylate" (polymer) - the rest. The second version of the agent comprises melatonin, xymedon and biodegradable polymeric base. The polymeric base is used as biological adhesive "Sulphacrylate" with the following ratio of components, wt %: melatonin - 5-25, xymedon - 3-25, adhesive "Sulphacrylate" (polymer) - the rest. The use of the biological adhesive "Sulphacrylate" is also claimed as a biodegradable polymeric base of veterinary implantable retard drug. |
|
|
Differential diagnostic technique and therapeutic approach to night eating syndrome Differential therapy is conducted depending on the number of night meals per a week. Sertraline in a dose of 100 mg is prescribed to the patients having two or less night meals per a week after going to bed and referred to a group of those with primarily evening manifestations of night eating syndrome. Agomelatine in a dose of 25 mg a day is prescribed to the patients having three or more night meals after going to bed and referred to a group of those with primarily night manifestations of night eating syndrome. The treatment continues until stable remission is achieved and further for 6 months. |
|
|
Drugs for treatment of helminthiasis of animals Drug for treatment of helminthiasis of animals comprises albendazole sulphoxide, butafosfan and water for injections with the following mass ratio of components, %: albendazole sulphoxide (n-[6-(propan-1-sulphinyl)-1H-1,3-benzodiazole-2-yl] methoxy carboximide acid) 5.0-10.0; butafosfan (1-butylamino-1-methyl) ethylphosphonic acid) 10.0-20.0; water for injections - the rest. |
|
|
Method for microinvasive phacoemulsification Tunnel approach and corneal paracentesis are formed. Introducing viscoelastic is followed by performing capsulorhexis, hydrodissection and hydrodelineation. An ultrasonic needle with an irrigation cuff is inserted through a tunnel incision into an eye cavity; an accessory irrigation instrument is inserted through the corneal paracentesis inclined to the tunnel incision. Fluid supply into an anterior eye chamber from an irrigation main line through a coaxial canal of the phaco needle and the accessory irrigation instrument simultaneously is actuated A nucleus of crystalline lens is destructed, and the crystalline mass are removed through an aspiration canal of the phaco needle simultaneously with the irrigation fluid. |
|
|
Method for rehabilitation of patients with infantile cerebral paralysis in form of spastic displegia Invention is applicable for rehabilitation of patients with infantile cerebral paralysis (ICP) in the form of spastic displegia. A heat therapy, general and differentiated massage are followed by placing a child into a training apparatus which represents a system of flexible rods with an underarm support, and performing a three-staged combined exercises including: 4-6-minute introductory exercises, 17-20-minute basic exercises and 3-5-minute final exercises. The procedure involves doing combined passive and active exercises including breathing exercises, coordination exercises, relaxation technique, exercises to normalise posture and position of head and extremities, exercises to develop flexion and extension of upper and lower extremities in accordance with the patent claim. |
Another patent 2551245.
| © 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English. |